Recent Posts

Post thread…
What happened to allergy positions? - Novartis

  • Has anyone seen their territory map

anonymous
Oct 15, 2024 at 10:39 AM
National Meeting ? - Genentech

  • We need National Meetings! Why?

    1. I need to get laid.
    2. I love watching the DEI nonsense play out in real time.
    3. MoTown Bands are fun to watch...not really. Especially the washed up ones.
    4. I like to make fun of the succups asking foolish questions.
    5. I laugh at the concept of "Breakfast with a Leader"...if your lucky you get to dine with one of our many incompetent fools running this ship aground...

anonymous
Oct 15, 2024 at 10:37 AM
cafead
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential - Pharma/Biotech Companies - In the News

  • via First, there was the Human Genome Project. The turn-of-the-century, international research program led to the sequencing and mapping of humanity’s entire genetic makeup at a fundamental level, paving the way for thousands of discoveries and treatments to address the world’s trickiest diseases.

    Now, chemical and biological “maps” have advanced far beyond what the Human Genome Project achieved, digging deeper into the inner workings of physics and the human body. And new technology like machine learning and AI has sparked a revolution in how complex and voluminous these roadmaps can be.

    article source

cafead
Oct 15, 2024 at 10:32 AM
cafead
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug - Pharma/Biotech Companies - In the News

  • via Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy.

    Notable's main focus has been volasertib, a polo-like kinase 1 (PLK1) inhibitor licensed from Boehringer three years ago that was being lined up for a phase 2 study in acute myeloid leukemia. The idea was to use Notable’s own Predictive Medicine Platform to identify patients most likely to benefit from the drug.

    article source

cafead
Oct 15, 2024 at 10:32 AM
cafead
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial - Pharma/Biotech Companies - In the News

  • via Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) has helped pre-symptomatic babies reach rare milestones after two years of treatment in a Phase II trial.

    article source

cafead
Oct 15, 2024 at 10:32 AM
Top Bottom
Back
Post thread…